Key result
The NeoVas sirolimus-eluting bioresorbable scaffold demonstrated a 3-year cumulative target lesion failure rate of 7.2% in low-risk patients with de novo coronary artery disease.
Why the study?
The long-term safety and efficacy of the novel NeoVas sirolimus-eluting bioresorbable scaffold for treating de novo coronary artery disease needed to be elucidated.
Meta-Analysis (n=1,103)
The NeoVas sirolimus-eluting bioresorbable scaffold demonstrated promising 3-year efficacy and safety with a 7.2% target lesion failure rate in low-risk patients with de novo coronary lesions.
Supports NeoVas scaffold evaluation in low-risk lesions; leaves open randomized comparisons versus metallic stents.
OBJECTIVES: We aimed to evaluate the long-term outcomes of the novel NeoVas sirolimus-eluting bioresorbable scaffold (BRS) for the treatment of de novo coronary artery disease. BACKGROUND: The long-term safety and efficacy of the novel NeoVas BRS are still needed to be elucidated. METHODS: A total of 1103 patients with de novo native coronary lesions for coronary stenting were enrolled. The primary endpoint of target lesion failure (TLF) was defined as a composite of cardiac death (CD), target vessel myocardial infarction (TV-MI), or ischemia-driven-target lesion revascularization (ID-TLR). RESULTS: A three-year clinical follow-up period was available for 1,091 (98.9%) patients. The cumulative TLF rate was 7.2% with 0.8% for CD, 2.6% for TV-MI, and 5.1% for ID-TLR. Additionally, 128 (11.8%) patient-oriented composite endpoint and 11 definite/probable stent thromboses (1.0%) were recorded. CONCLUSIONS: The extended outcomes of the NeoVas objective performance criterion trial demonstrated a promising 3-year efficacy and safety of the NeoVas BRS in low-risk patients with low complexity in terms of lesions and comorbidities.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2023) conducted a meta-analysis in de novo coronary artery disease (n=1,103). NeoVas sirolimus-eluting bioresorbable scaffold (BRS) was evaluated on Target lesion failure (TLF) defined as a composite of cardiac death (CD), target vessel myocardial infarction (TV-MI), or ischemia-driven-target lesion revascularization (ID-TLR). The NeoVas sirolimus-eluting bioresorbable scaffold demonstrated a 3-year cumulative target lesion failure rate of 7.2% in low-risk patients with de novo coronary artery disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: